Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

KYMRAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ721.72+ 1.34%S&P 500 · SPY770.01+ 0.61%Dow Jones · DIA523.40+ 0.08%Russell 2000 · IWM280.14+ 1.14%

Morgan Stanley Maintains Overweight on Kymera Therapeutics, Raises Price Target to $146
Morgan Stanley analyst James Quigley maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $135 to $146.
Benzinga04:4714 Hours AgoKYMR+2.5%

09:00-18:00Yesterday2 Stories

Could You Have Seen The Run In Kymera Stock Coming?
For questions about this article or underlying research, email help@trefis.com.
Yahoo17:34KYMR+2.5%
Will Axsome Therapeutics (AXSM) Report Negative Earnings Next Week? What You Should Know
Axsome (AXSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Yahoo09:00

16:00Oct 221 Story

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
WATERTOWN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2026 financial results on October 29, 2026. The Company will host a video conference call and webcast at 8:30 a.m. ET that day. To join the video call or view the livestreamed webcast, please register via this link, or visit “News and Events” in
Yahoo16:01KYMR+2.5%

09:00Oct 191 Story

Can KYMR's Targeted Protein Degradation Pipeline Drive Future Growth?
Kymera Therapeutics advances its targeted protein degradation pipeline, with KT-621 trials in atopic dermatitis and asthma marking key milestones amid competition in the field.
Yahoo09:08KYMR+2.5%

04:00Oct 92 Stories

Kymera: Over-Hyped, Or Developing Next Dupixent? We'll Find Out Very Soon
Kymera Therapeutics (KYMR) eyes pivotal BROADEN2 Phase 2b data for KT-621, a STAT6 degrader in atopic dermatitisâupside vs. Dupixent. See more here.
SeekingAlpha04:30KYMR+2.5%
This American Express Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiate coverage: Outperform on American Express and Kymera, Overweight on Kratos, Hold on IBM and Neutral on Duos.
Benzinga04:21KYMR+2.5%

03:00Oct 91 Story

Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140
Raymond James analyst Thomas Deal initiates coverage on Kymera Therapeutics (NASDAQ:KYMR) with a Outperform rating and announces Price Target of $140.
Benzinga03:13KYMR+2.5%